Approved August 1998
Vitravene Injection for the local treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS) who are intolerant of or have a contraindication to other treatment(s) for CMV retinitis or who were insufficiently responsive to previous treatment(s) for CMV retinitis.
The use of Vitravene does not provide treatment for systemic CMV disease.
Vitravene injection is not a cure for CMV retinitis, and some immunocompromised patients may continue to experience progression of retinitis during and following treatment. Patients receiving Vitravene should be advised to have regular ophthalmologic follow-up examinations. Patients may also experience other manifestations of CMV disease despite Vitravene therapy.
Abdomianl pain, anemia, diarrhea, fever, headache, infection, nausea, pneumonia, rash, etc.
The Vitravene Injection drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.